8-K: Scilex Holding Co. Announces Preliminary Q1 2024 Results, Plans Cost Reductions

Scilex Holding Company reported preliminary unaudited first-quarter 2024 results showing growth in ZTlido sales and announced plans to reduce R&D and administrative expenses.

Summary

• Scilex Holding Company has released preliminary, unaudited financial results for the first quarter of 2024.
• ZTlido gross sales are estimated to be between $34.0 million and $38.0 million, compared to $27.5 million in the first quarter of 2023, representing a growth of 24% to 38%.
• ZTlido net sales are estimated to be between $12.0 million and $13.0 million, compared to $10.6 million in the first quarter of 2023, representing a growth of 13% to 23%.
• The company plans to reduce research and development and other administrative expenses in 2024.
• Scilex intends to focus on late-stage pipeline programs like SP-102 and expand commercial and production activities.
• The company expects to launch Gloperba, a gout prophylaxis product, in the first half of 2024.
• Scilex has resolved issues with co-pay savings card processing for ZTlido following a cyber-attack on Change Healthcare.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong sales growth and cost reduction plans, but the preliminary nature of the results and the mention of risks temper the overall sentiment.

Positives

• The company experienced significant year-over-year growth in both gross and net sales of ZTlido.
• Scilex is actively working to control costs by reducing R&D and administrative expenses.
• The company is focusing on late-stage pipeline programs, which could lead to future revenue growth.
• The launch of Gloperba in the first half of 2024 is expected to contribute to revenue.
• The resolution of the co-pay savings card processing issue is a positive step for patient access.

Negatives

• The financial results are preliminary and unaudited, and actual results may differ materially.
• The company experienced a disruption in co-pay savings card processing due to a cyber-attack on Change Healthcare, impacting patients and customers.

Risks

• The preliminary financial results are subject to change and may differ materially from actual results.
• The company's future success depends on the successful development and commercialization of its product candidates.
• There are risks associated with the unpredictability of trading markets and whether a market will be established for Scilex's common stock.
• The company faces risks related to regulatory approvals, market acceptance, and intellectual property.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Scilex expects continued sales growth in the non-opioid pain management market, including potential growth from the launch of Gloperba in the first half of 2024. The company also plans to reduce R&D and administrative expenses to focus on late-stage pipeline programs and commercial expansion.

Management Comments

• We believe the non-opioid pain management prescription market is adopting our products rapidly and should be reflected in continued sales growth.
• Our intention is to drive value creation and ensure we remain ahead of rising demand for our non-opioid products.

Industry Context

The announcement aligns with the broader industry trend of focusing on non-opioid pain management solutions. Scilex is positioning itself to capitalize on this trend with its existing products and pipeline.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, the growth rates for ZTlido sales suggest a positive trajectory compared to the previous year.
• The focus on cost reduction and pipeline development is a common strategy in the pharmaceutical industry, particularly for companies in the growth phase.
• The launch of Gloperba in the first half of 2024 is a key milestone for Scilex, and its success will be compared to other new product launches in the pharmaceutical sector.
• Companies like Pacira BioSciences, Inc. and Heron Therapeutics, Inc. are also focused on non-opioid pain management, and Scilex's performance will be benchmarked against these and other competitors in the space.

Stakeholder Impact

• Shareholders may view the sales growth and cost reduction plans positively.
• Employees may be impacted by the planned reduction in R&D and administrative expenses.
• Customers and patients will benefit from the resolution of the co-pay savings card processing issue and the potential launch of new products.
• Suppliers and creditors may be impacted by the company's financial performance and strategic decisions.

Next Steps

• Scilex plans to launch Gloperba in the first half of 2024.
• The company will continue to focus on late-stage pipeline programs such as SP-102.
• Scilex will expand commercial and production activities for its products.
• The company plans to initiate a Phase 2 clinical trial for SP-104 in 2024.

Key Dates

Keywords

ZTlido, Scilex, Gloperba, SP-102, SP-103, SP-104, Non-opioid pain management, Financial results, Pharmaceuticals, R&D, Net sales, Gross sales